Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
Blood|July 1, 1996
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with ageL Busque, R Mio, J Mattioli, et al.Nature Genetics|October 3, 1999
Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemiaW J Song, M G Sullivan, R D Legare, et al.Cancer Research|September 1, 1995
Analysis of meningiomas by methylation- and transcription-based clonality assaysJ Zhu, M P Frosch, L Busque, et al.Leukemia|November 14, 2008
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasmsL Bernard, C Belisle, L Mollica, et al.Cancer Genetics and Cytogenetics|December 7, 2000
Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemiaM L Loh, Y Samson, E Motte, et al.Blood|January 7, 1998
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteinsM Carroll, S Ohno-Jones, S Tamura, et al.Leukemia|October 19, 2011
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515LG Wernig, M G Kharas, A Mullally, et al.Blood|December 9, 1998
Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemiaM L Loh, L B Silverman, M L Young, et al.Blood|February 25, 1999
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitorM H Tomasson, I R Williams, R Hasserjian, et al.The New England Journal of Medicine|July 21, 1994
Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative diseaseC L Willman, L Busque, B B Griffith, et al.Pageof 9